mirvetuximab soravtansine-gynx (Elahere)

From Aaushi
Jump to navigation Jump to search

Indications

Dosage

Adverse effects

* boxed warning of ocular toxicity

Mechanism of action

More general terms

References

  1. 1.0 1.1 FDA Drug Approvals. Nov 14, 2022 FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRa positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant
    Otto MA FDA Approves Mirvetuximab Soravtansine for Folate Receptor Alpha-Positive Ovarian Cancer. Medscape. Nov 15, 2022 https://www.medscape.com/viewarticle/984055
  2. Moore KN, Oza AM, Colombo N et al Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021 Jun;32(6):757-765. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33667670 Clinical Trial. https://www.annalsofoncology.org/article/S0923-7534(21)00157-5/fulltext